Gilead Sciences (GILD) announced on Thursday that its Phase 3 ARTISTRY-1 trial, which tested its new single-tablet regimen of bictegravir and lenacapavir in adults with HIV, reached the primary ...

(Reuters) -‌Merck said ‌on Wednesday that ⁠its ‌experimental oral HIV ‍treatment met the main ‌goal of a late-stage trial.⁠ (Reporting by ‍Sneha ⁠S K; ⁠editing by ‌Tasim ‌Zahid) The FDA Just Added 9 ...

Merck (MRK) announced on Wednesday that its single-tablet antiviral regimen, doravirine and islatravir for adults with HIV, was found to be non-inferior to Gilead’s (GILD) once-daily HIV pill Biktarvy ...

The biopharmaceutical company said Monday that the treatment, a once-daily single tablet of bictegravir and lenacapavir, was found to be statistically non-inferior to an existing treatment, Biktarvy.

Researchers conducted a retrospective, multinational study across 15 European treatment centers to assess the efficacy and tolerability of DTG/3TC vs BIC/TAF/FTC as first‑line therapy in ...

Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. Biktarvy sales and Descovy for pre-exposure prophylaxis (PrEP) have fueled GILD’s ...

Europe is failing to test and treat HIV early, with over half (54%) of all diagnoses in 2024 being made too late for optimal treatment. New data released today by the European Centre for Disease ...

(Reuters) -‌Merck said ‌on Wednesday that ⁠its ‌experimental oral HIV ‍treatment met the main ‌goal of a late-stage trial.⁠ ...